Cytomegalovirus infection overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AKI}}
{{CMG}}; {{AE}} {{AKI}}
==Overview==
==Overview==
CMV infection is caused by cytomegalovirus, belongs to the family [[Herpesviridae]]. Transmission of CMV occurs from person to person and primary CMV infection causes activation of the immune system and resulting in a mononucleosis like presentation with hepatitis in immunocompromised individuals and few immunocompetent individuals. Reactivation can occur in response to inflammatory stimuli, physiologic stress and immunosuppression releasing new virions that can infect new cells causing CMV end organ infection. CMV infection can affect the eye, gastrointestinal tract and the central nervous system. Primary infection in majority of patients have a mononucleosis like presentation. Patients with immunosuppression have symptoms related to the affected organ system. Common complications of CMV infection in immunocompromised patients include CMV retinitis, CMV colitis, CMV encephalitis, CMV pneumonia and CMV myocarditis. CMVis associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections increasing morbidity and mortality of the patients. Antiviral therapy is the primary modality of treatment. Duration of therapy and the antiviral agents are selected based on the severity of the disease, location of the disease and the level of immunosuppression. Ganciclovir and valganciclovir are the commonly used antiviral drugs for the treatment of CMV infection.


== Historical Perspective ==
== Historical Perspective ==

Revision as of 21:24, 25 May 2017

Cytomegalovirus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cytomegalovirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cytomegalovirus infection overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cytomegalovirus infection overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cytomegalovirus infection overview

CDC on Cytomegalovirus infection overview

Cytomegalovirus infection overview in the news

Blogs on Cytomegalovirus infection overview

Directions to Hospitals Treating Cytomegalovirus infection

Risk calculators and risk factors for Cytomegalovirus infection overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Overview

CMV infection is caused by cytomegalovirus, belongs to the family Herpesviridae. Transmission of CMV occurs from person to person and primary CMV infection causes activation of the immune system and resulting in a mononucleosis like presentation with hepatitis in immunocompromised individuals and few immunocompetent individuals. Reactivation can occur in response to inflammatory stimuli, physiologic stress and immunosuppression releasing new virions that can infect new cells causing CMV end organ infection. CMV infection can affect the eye, gastrointestinal tract and the central nervous system. Primary infection in majority of patients have a mononucleosis like presentation. Patients with immunosuppression have symptoms related to the affected organ system. Common complications of CMV infection in immunocompromised patients include CMV retinitis, CMV colitis, CMV encephalitis, CMV pneumonia and CMV myocarditis. CMVis associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections increasing morbidity and mortality of the patients. Antiviral therapy is the primary modality of treatment. Duration of therapy and the antiviral agents are selected based on the severity of the disease, location of the disease and the level of immunosuppression. Ganciclovir and valganciclovir are the commonly used antiviral drugs for the treatment of CMV infection.

Historical Perspective

In 1881, Ribbert described the presence of inclusion bodies in the cells in sections of kidney of a still born. In 1960, Thomas H.Weller from Harvard University, coined the term "cytomegalovirus" and isolated the virus from the urine sample of an infant with generalized disease.

Classification

Cytomegalovirus infection can be classified based on the organ system involved into the following: CMV retinitis, CMV colitis, CMV esophagitis, CMV pneumonitis and CMV encephalitis.

Pathophysiology

Transmission of CMV occurs from person to person and primary CMV infection causes activation of the immune system and resulting in a mononucleosis like presentation with hepatitis in immunocompromised individuals and few immunocompetent individuals. Reactivation can occur in response to inflammatory stimuli, physiologic stress and immunosuppression releasing new virions that can infect new cells causing CMV end organ infection.

Causes

CMV infection is caused by cytomegalovirus. It belongs to order Herpesvirales, in the family Herpesviridae, in the subfamily Betaherpesvirinae.

Differential Diagnosis of Cytomegalovirus infection

CMV infection can affect the eye, gastrointestinal tract and the central nervous system. Diagnosis of CMV requires differentiation of infections and diseases presenting with similar features. Majority of the patients with CMV end organ infection are immunosuppressed. Therefore CMV infection must be suspected in all the patients presenting with immunosuppression.

Epidemiology and Demographics

Cytomegalovirus (CMV) infection is seen approximately 40-90% of the world population.

Risk Factors

Patients with the following conditions are at a higher risk for developing symptomatic cytomegalovirus infection include patients with solid organ transplanthematological stem cell transplantAIDS and existing T-cell deficiency.

Screening

There is no standard screening recommended for cytomegalovirus infection due to the high seroprevalence.

Natural History, Complications and Prognosis

Primary CMV infection takes place in childhood and early adolescence is asymptomatic. After the resolution of the primary infection CMV is latent in the mononuclear leukocytes. Reactivation in immunocompetent patients presents with mononucleosis like syndrome, but severe infection can occur in elderly and critically ill patients. Common complications of CMV infection in immunocompromised patients include CMV retinitis, CMV colitis, CMV encephalitis, CMV pneumonia and CMV myocarditis. CMVis associated with increased risk of graft versus host disease, myelosuppression, and invasive bacterial and fungal infections increasing morbidity and mortality of the patients.

Diagnosis

History and Symptoms

Primary infection in majority of patients have a mononucleosis like presentation. Patients with immunosuppression have symptoms related to the affected organ system. Retinitis presents with blurred vision and floaters. Colitis presents with abdominal pain and bloody diarrhea. Pneumonitis is usually asymptomatic. Neurologic infection presents with altered mental status and focal neurological deficits.

Physical Examination

The appearance of the patient depends on the stage of the disease. The patient may look very healthy or be ill-looking and cachectic. On fundus examination fluffy yellow-white retinal lesions, with or without intraretinal hemorrhages can be demonstrated in patients with CMV retinitis. Abdominal distension and tenderness can be present on examination in patients with CMV colitis. In patients with CMV encephalitis altered mental status and focal neurological deficits are present.

Laboratory Findings

There are no specific laboratory findings associated with CMV infection. Elevated ESR and a low lymphocyte count may be present in patients with complications. Diagnosis is usually done by demonstration of the inclusion bodies from the tissue biopsies or by a positive PCR for CMV DNA.

Electrocardiogram

There are no EKG changes associated with cytomegalovirus infection.

Chest X-Ray

Chest X-Ray in cytomegalovirus pneumonitis demonstrates diffuse pulmonary interstitial infiltrates.

CT Scan

CT abdomen in patients with colitis demonstrates colonic thickening and the presence of periventricular enhancement on a brain CT is suggestive of ventriculoencephalitis.

MRI

Periventricular enhancement is present in patients with ventriculoencephalitis on brain MRI.

Echocardiography

There are no echocardiography findings associated with CMV infection.

Other imaging findings

CMV infection is diagnosed by demonstration of intranuclear inclusion bodies and a positive PCR, therefore there are no other specific imaging findings for CMV infection.

Other Diagnostic Tests

Other diagnostic studies helpful for the diagnosis of CMV infection include upper GI endoscopy, colonoscopy, serology and PCR.

Treatment

Medical Therapy

Antiviral therapy is the primary modality of treatment. Duration of therapy and the antiviral agents are selected based on the severity of the disease, location of the disease and the level of immunosuppression. Ganciclovir and valganciclovir are the commonly used antiviral drugs for the treatment of CMV infection.

Surgery

Surgical intervention is not recommended for the management of cytomegalovirus infection.

Prevention

Primary Prevention

Regular hand washing is a commonly recommended step to decrease the spread of infections and healthcare providers should follow standard precautions to prevent nosocomial transmission.

Secondary Prevention

Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.

References